{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:03:43Z","timestamp":1784099023493,"version":"3.55.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A subset of cancer patients receiving monoclonal antibody PD-1\/PD-L1 inhibitors may develop immune checkpoint inhibitor (ICI)-related neurological complications, such as ICI-related myasthenia gravis(MG)-myositis overlap syndrome and ICI-related myocarditis. Standard management typically involves intravenous immunoglobulin (IVIG), plasma exchange (PE), and high-dose corticosteroids. The use of efgartigimod, a neonatal Fc receptor blocker, for the treatment of ICI-related MG-myositis overlap syndrome remains investigational, with only four relevant cases all representing overlap syndromes (MG with myositis, with or without myocarditis) \u2014 reported to date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This report examines the therapeutic effect of efgartigimod in a patient with cervical cancer who developed ICI-related MG-myositis overlap syndrome after receiving tislelizumab, an anti-PD-1 antibody.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical data from the patient was collected. Relevant laboratory tests and examinations were conducted. Efgartigimod treatment was administered, and clinical severity was evaluated using standardized assessment scales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A 69-year-old female with cervical cancer developed bilateral ptosis, dysarthria, and limb weakness following tislelizumab therapy. Examination revealed asymmetric ptosis, weak eye closure, and positive fatigability test. Serum creatine kinase was markedly elevated (553.82 U\/L); electromyography showed myopathic changes with fibrillation potentials, while repetitive nerve stimulation was negative. Neostigmine test was positive, and anti-acetylcholine receptor antibodies were detected. She was diagnosed with ICI-related MG-myositis overlap syndrome. After four infusions of efgartigimod (10 mg\/kg), creatine kinase normalized, the Activities of Daily Living (ADL) score decreased from 10 to 1, and the Quantitative Myasthenia Gravis (QMG) score improved from 16 to 5. The patient was asymptomatic at the 5 months follow-up with no need for a second treatment cycle.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Efgartigimod produced a positive therapeutic effect in this case with ICI-related MG-myositis overlap syndrome. The therapy was well-tolerated, and no adverse events were reported.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1818836","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:04:37Z","timestamp":1784095477000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efgartigimod in the treatment of immune checkpoint inhibitor-related myasthenia gravis -myositis overlap syndrome: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Ke","family":"Li","sequence":"first","affiliation":[{"name":"Department of Neurology, The Second Affiliated Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Second Affiliated Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiji","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Second Affiliated Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Second Affiliated Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Second Affiliated Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqing","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Second Affiliated Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueliang","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Second Affiliated Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101192","article-title":"Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study","volume":"50","author":"Plomp","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1671964","article-title":"Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report","volume":"16","author":"Lu","year":"2025","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12883-025-04288-0","article-title":"Efgartigimod therapy for immune checkpoint inhibitor-associated myasthenia gravis with myositis: a case report","volume":"25","author":"Qi","year":"2025","journal-title":"BMC Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/1750743x.2025.2517522","article-title":"Pembrolizumab-induced myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS) treated with Efgartigimod: case report","volume":"17","author":"Cobelas-Cartagena","year":"2025","journal-title":"Immunotherapy"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.12659\/ajcr.951872","article-title":"Efgartigimod as rescue therapy for PD-1 inhibitor-associated myasthenia gravis, myocarditis, and myositis (MMM) syndrome: a 2-case report and literature review","volume":"27","author":"Liu","year":"2026","journal-title":"Am J Case Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02407-8","article-title":"Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier","volume":"22","author":"Vafaei","year":"2022","journal-title":"Cancer Cell Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.800879","article-title":"Immune checkpoint inhibitor-associated colitis: from mechanism to management","volume":"12","author":"Tang","year":"2021","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1646231","article-title":"Clinical features and HLA typing of immune checkpoint inhibitor-associated myasthenia gravis, myocarditis and myositis","volume":"15","author":"Lin","year":"2025","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","article-title":"Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors","volume":"18","author":"Kao","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Suarez-Almazor","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.13727","article-title":"Immune checkpoint inhibitors for patients with preexisting autoimmune neurologic disorders","volume":"8","author":"Fletcher","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251333518","article-title":"Eculizumab as fast-acting rescue therapy for pembrolizumab-induced impending crisis state of myasthenia gravis: a case report","volume":"18","author":"Huang","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-07190-0","article-title":"Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors","volume":"45","author":"Fionda","year":"2024","journal-title":"Neurol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2025.2497840","article-title":"Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases","volume":"21","author":"Gwathmey","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"key":"B17","article-title":"Intravenous immunoglobulin (IVIG)","volume-title":"Statpearls [Internet]","author":"Arumugham","year":"2023"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000218081","article-title":"Comparative study of sporadic and immune checkpoint inhibitor-related forms of myasthenia gravis-myositis overlap syndrome","volume":"106","author":"Lauletta","year":"2026","journal-title":"Neurology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200314","article-title":"Clinical course of neurologic adverse events associated with immune checkpoint inhibitors: focus on chronic toxicities","volume":"11","author":"Rossi","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcae006","article-title":"Immune checkpoint inhibitor-related myasthenia gravis, myositis and myocarditis: a triad but not at the same time","volume":"117","author":"Cooksley","year":"2024","journal-title":"QJM"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1818836\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:04:37Z","timestamp":1784095477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1818836\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2026.1818836"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1818836","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1818836"}}